SSIS

PolyPid Announces Planned CEO Transition

Retrieved on: 
Monday, January 3, 2022
Growth, Private Securities Litigation Reform Act, Tel Aviv University, Brain, Industry, U.S. Securities and Exchange Commission, Economics, Polypide, PLEX, Board, MBA, Trial of the century, Clinical trial, GLOBE, Compugen, Company, Leadership, NASDAQ, Nature, Â, CEO, Achievement, Therapy, Board of directors, Nasdaq, TASE, Strategic planning, Security (finance), SSIS, History, Technology, Director, Forward-looking statement, Management

Since joining PolyPid seven years ago, she has been instrumental in guiding our financial, strategic and operational objectives.

Key Points: 
  • Since joining PolyPid seven years ago, she has been instrumental in guiding our financial, strategic and operational objectives.
  • Under his leadership, PolyPid is in the strongest operational and financial position in its history, and we thank Amir for his significant contributions as CEO over the past 11 years.
  • It has been an honor to have served as CEO of PolyPid throughout the development phase of our company, stated Mr. Weisberg.
  • Separately, PolyPid announced that Shaul Mukhtar, Ph.D., Chief Operating Officer of PolyPid, will be retiring from the Company, effective March 2022, following two and a half years with PolyPid.

Outlook on the Sterilization Services Global Market to 2028 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 30, 2021
General Health, Health, Surgery, Growth, Infection, Industry, COVID-19, Filtration, Geography, Aladdin (food & beverage containers), CAGR, CDC, United States Environmental Protection Agency, EPA, EPD, Hospital-acquired infection, HIV, Health care, Knowledge, Hospital, Prevalence, Food, Hepatitis B, Incidence, HIV/AIDS, Subclinical infection, Sterilization, ETO, BGS, Lists of countries and territories, Patient, Eyeish, SSIS, WHO, Time, Stockholm Environment Institute US Center, Method, HAI, Medical device, Marketing

The "Global Sterilization Services Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Method, Service Type, Mode of Delivery, End User; and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Sterilization Services Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Method, Service Type, Mode of Delivery, End User; and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The sterilization services market is projected to reach US$ 4,717.56 million by 2028 from 3,023.50 million in 2021; it is expected to grow at a CAGR of 6.6 % from 2021 to 2028.
  • However, stringent regulations regarding chemical emissions hinder the sterilization services market growth.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Hospital Bedsheet & Pillow Cover Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021
Health, Hospitals, Urinary tract infection, Hygiene, Bloodstream infections, Bedsheet, MEA, Hospital, Infection, USD, American Hospital Association, Pneumonia, Time-invariant system, Reusability, Prevalence, Subclinical infection, CAGR, Eyeish, Death, CDC, Center, SSIS, APAC, Taiwan Centers for Disease Control, Growth, Maintenance, Linens

The "Hospital Bedsheet & Pillow Cover Market Size, Share & Trends Analysis Report By Type (Bedsheet, Pillow Cover), By Product (Reusable, Disposable), By Region (APAC, MEA), And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hospital Bedsheet & Pillow Cover Market Size, Share & Trends Analysis Report By Type (Bedsheet, Pillow Cover), By Product (Reusable, Disposable), By Region (APAC, MEA), And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global hospital bedsheet & pillow cover market size is expected to reach USD 8.1 billion by 2028, registering a CAGR of 6.6%
    Increasing number of surgeries performed and hospitalizations, is the key factor driving the market growth.
  • Moreover, the rising prevalence of nosocomial infections, such as bloodstream, urinary tract, surgical site infections, and pneumonia, will boost the market growth over the forecast period.
  • Thus, with increasing cases of nosocomial infections, the demand for preventive services will increase, thereby, boosting the demand for hospital pillow covers and bedsheets.

The Global Infection Control Market Will Grow to USD 42.907 Billion by 2026, at a CAGR of 10.46% - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 16, 2021
Medical Supplies, Health, Hospital, Sodium hypochlorite, Food, Pseudomonas, FDA, Eyeish, Degenerative disease, Conditional sentence, Bacteria, Klebsiella, Pneumonia, Bed, Hospital-acquired infection, Disinfectant, Infection, Ethylene oxide, Awareness, Population, Growth, Mask, Human, Catheter-associated urinary tract infection, PPE, Industry, Incidence, Environment, Subclinical infection, Criticism of the Food and Drug Administration, COVID-19, CAGR, Ventilator-associated pneumonia, SSIS, Substance-related disorder, Urinary tract infection, Patient, Hygiene, Mortality, Immune system, BSI Steel, Escherichia coli, MRSA, HAI, Bloodstream infections, Health, Sterilization, Medical imaging, Vaccine, Medical device, Sewage, Pharmaceutical industry, Enterococcus

The "Global Infection Control Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infection Control Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global infection control market is projected to grow at a CAGR of 10.46% to reach US$42.907 billion by 2026, from US$21.384 billion in 2019.
  • Due to all these reasons, the infection control market has seen a large growth owing to the proper use of sterilization and disinfecting practices being used in healthcare facilities.
  • North America is expected to account for the largest share of the infection control market during this period.

Abre.io Announces Partnership with SSIS CoLab Offering Evidenced-Based Student Well-being and Mental Health Solutions for Schools

Retrieved on: 
Tuesday, December 14, 2021
SSIS, Child, CIP, Doctor of Philosophy, Classroom, Adult, Arizona State University, Parent, Resonance, SEL, CEO, Social skills, Mental health, K-12, Multimedia, School, Education, Student, Partnership, Medical imaging, Medicine, Open Your Eyes (1997 film)

The integration between Abre and SSIS CoLab will provide critical information regarding the whole child by synthesizing data provided by students, teachers, and parents regarding a child's well-being.

Key Points: 
  • The integration between Abre and SSIS CoLab will provide critical information regarding the whole child by synthesizing data provided by students, teachers, and parents regarding a child's well-being.
  • The direct integration between Abre and SSIS CoLab will enhance Abre's student dashboard with CASEL aligned metrics from the Social Skills Improvement System (SSIS) Brief Scales with an optional mental health component.
  • For decades, SSIS CoLab researchers, authors and their partners at Resonant Education have championed sound social emotional skills assessment and evidence-based intervention practices.
  • "SSIS CoLab is excited to collaborate with Abre to scale the distribution and impact of our evidence-based, one-of-a-kind assessment and intervention solution to advance all children's social, emotional, and mental health," said Stephen N. Elliott, President of SSIS CoLab.

PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

Retrieved on: 
Thursday, November 18, 2021
SHIELD, Private Securities Litigation Reform Act, Patient, Security (finance), Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Technology, Breakthrough therapy, Surgery, Forward-looking statement, Company, Polypide, U.S. Securities and Exchange Commission, Food, Therapy, PLEX, Disease, Nature, Colorectal surgery, SSIS, QIDP, GLOBE, 500th SS Parachute Battalion, Hospital, FDA, Infection, Pharmaceutical industry

SHIELD I is a pivotal study evaluating D-PLEX100 for the prevention of surgical site infections (SSIs) in abdominal surgery.

Key Points: 
  • SHIELD I is a pivotal study evaluating D-PLEX100 for the prevention of surgical site infections (SSIs) in abdominal surgery.
  • The trial will continue with patient enrollment, toward approximately 900 patients, in about 60 centers across the United States, Europe and Israel.
  • A blinded review of the overall event rates will commence once the 500th patient completes the 30-day follow-up and is evaluated for the primary endpoint.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

PolyPid Appoints New Oncology Advisory Board Member

Retrieved on: 
Tuesday, November 16, 2021
Traffic barrier, Cancer, Private Securities Litigation Reform Act, Neurosurgery, MD, Drug discovery, University, Security (finance), Technology, Food, GBM, Brain, Research, MD Anderson Cancer Center, Forward-looking statement, Food and Drug Administration, Polypide, Palestinian National Interest Committee, Docetaxel, Company, U.S. Securities and Exchange Commission, GLOBE, Glioblastoma, Therapy, Nature, Monroe Dunaway Anderson, Death, SSIS, Survival, Patient, PLEX, Pharmaceutical industry

PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D., to its Oncology Advisory Board.

Key Points: 
  • PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D., to its Oncology Advisory Board.
  • In September 2021, PolyPid announced positive preclinical data for its intra-tumoral OncoPLEX in animal models of Glioblastoma Multiform (GBM).
  • I am elated that Dr. Lang has agreed to join PolyPids Oncology Advisory Board, said Amir Weisberg, Chief Executive Officer of PolyPid.
  • Dr. Lang receives compensation as a member of the Oncology Advisory Board, and this financial relationship has been disclosed to MD Andersons Conflict of Interest Committee in accordance with institutional policy.

PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
SHIELD, NDA, Colorectal surgery, Investigational New Drug, Agency, Commercial, Acceleration, Food, GBM, Insurance, Brain, Financial result, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Polypide, Â, Conference, Company, Research, GLOBE, D&O, Therapy, SSIS, Survival, Marketing, Patient, FDA, Pharmaceutical industry, Medical device, Medicine, Cryptocurrency, Ridesharing company

PETACH TIKVA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focusing on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2021.

Key Points: 
  • FDA agreement that a single pivotal Phase 3 study is sufficient for potential approval will extend PolyPids cash runway to year end 2022.
  • Last-patient-in from SHIELD I is expected to enroll during the second quarter of 2022 with top line results 2 months thereafter.
  • Our cash runway now extends to year-end 2022, a significant improvement over our prior target of the second quarter of 2022.
  • PolyPid expects that its cash on hand will be sufficient to fund operations until the end of 2022.

Global Hospital Acquired Infections Therapeutic Markets 2020-2027: Rise in Approval and Launch of New Drugs Bodes Well for the Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 20, 2021
Hospitals, Pharmaceutical, Health, SSIS, Infection, CAGR, Prevalence, Clostridioides, Merck, Ventilator-associated pneumonia, Avibactam, Shanda, Colon, Subclinical infection, New York State Department of Health, D, USD, FDA, Adoption, New Drug Application, Hospital, Clostridioides difficile infection, Eyeish, Conditional sentence, Antiviral drug, HAI, Therapy, CDI, Ceftazidime, Pharmaceutical industry

The "Global Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), by Infection Type, by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), by Infection Type, by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global hospital acquired infections therapeutic market size is expected to reach USD 12.5 billion by 2027.
  • The market is expected to expand at a CAGR of 2.4% from 2020 to 2027.
  • The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.

SolarWinds Gives Data Pros the Tools for DataOps Success With Database Mapper and Task Factory

Retrieved on: 
Tuesday, October 19, 2021
Data Management, Security, Technology, Software, Networks, Hardware, Cloud, Software, DataOps, Documentation, Privacy, PII, Software as a service, SolarWinds, Organization, Microsoft Visual Studio, NYSE, Growth, SQL, Multimedia, Microsoft, Salesforce, ETL, Education, Live, Database, SWI, SQL Server, Server, Compliance, Efficiency, Solution, Metadata, SSIS, Environment, Data management, Computer data storage, Management, Information technology, Video game console

View the full release here: https://www.businesswire.com/news/home/20211019005091/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211019005091/en/
    SolarWinds Database Mapper provides a visual display of data lineage for impact analysis, so you can immediately understand data dependencies across the entire data stack.
  • Database Mapper and Task Factory are designed to help data pros master their data environments, streamline data warehouse management, and develop and run data-centric apps in the cloud, enabling organizations to reap the benefits of DataOps.
  • With Database Mapper and Task Factory, SolarWinds delivers powerful, easy-to-use solutions for implementing successful DataOps strategies so organizations can maximize the value of their data and cloud migrations faster and more efficiently.
  • SolarWinds Database Mapper simplifies DataOps implementation by providing a one-stop shop for data teams to easily maintain current documentation and visually track data dependencies and comparisons across the environment, streamlining business-critical data projects.